Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
用户slK1Kxicm8Dw
1小时前
8
10
求助中
帖子自动结束时间: 2026-05-04 15:00:03
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1159/000549955
文献链接: https://karger.com/article/doi/10.1159/000549955
其他信息:
出版社: S. Karger AG
作者: Stephen Lam Chan; Masatoshi Kudo; Bruno Sangro; Robin Kate Kelley; Jee Hyun Kim; Binh Pham; Jung Yong Hong; Dirk-Thomas Waldschmidt; Donatella Marino; Jie Xin Joycelyn Lee; René Gerolami; Adam M. Burgoyne; Qiao Li; Hitomi Nakamura; Peng Sun; Boris Baur; Lorenza Rimassa
